Drug Combination Details
| General Information of the Combination (ID: C06446) | |||||
|---|---|---|---|---|---|
| Name | Fisetin NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Testicular carcinoma
[ICD-11: 2C80]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAK | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP7 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NT2-D1 | CVCL_3407 | Embryonal carcinoma | Homo sapiens | ||
| In-vivo Model | NT2/D1 cells (106) mixed with Matrigel were implanted into 6-week-old athymic nude mice bearing the nu/nu gene [NIH(s) (nu/nu)] and housed under pathogen-free conditions. | |||||
| Experimental
Result(s) |
Addition of fisetin to cisplatin activates both the mitochondrial and the cell death receptor pathway and could be a promising regimen for the elimination of embryonal carcinoma cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors. Mol Cancer Ther. 2011 Feb;10(2):255-68. | |||
